A share price of Rallybio Corp [RLYB] is currently trading at $0.38, up 27.85%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RLYB shares have gain 11.57% over the last week, with a monthly amount glided 17.32%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rallybio Corp [NASDAQ: RLYB] stock has seen the most recent analyst activity on April 09, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, JP Morgan downgraded its rating to Neutral on May 15, 2024. On February 07, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $1.50 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $18 on April 17, 2023. Wedbush initiated its recommendation with a Outperform and recommended $17 as its price target on April 10, 2023. JP Morgan started tracking with a Overweight rating for this stock on December 09, 2022, and assigned it a price target of $21. In a note dated February 22, 2022, JMP Securities initiated an Mkt Outperform rating and provided a target price of $32 on this stock.
Rallybio Corp experienced fluctuations in its stock price throughout the past year between $0.22 and $1.73. Rallybio Corp [NASDAQ: RLYB] shares were valued at $0.38 at the most recent close of the market.
Analyzing the RLYB fundamentals
Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -59.41%, Pretax Profit Margin comes in at -56.25%, and Net Profit Margin reading is -56.82%. To continue investigating profitability, this company’s Return on Assets is posted at -0.83, Equity is -0.72 and Total Capital is -0.93. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Rallybio Corp [NASDAQ:RLYB] is 14.68. Further, the Quick Ratio stands at 14.68, while the Cash Ratio is 3.78. Considering the valuation of this stock, the price to sales ratio is 18.41, the price to book ratio is 0.29.
